Thyrotropin Alfa
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Thyrotropin Alfa: From Thyroid Cancer Diagnostic Support to Migraine Disorder
One-Sentence Summary
Thyrotropin alfa is recombinant human thyroid-stimulating hormone (TSH), used as a diagnostic and adjunctive agent in thyroid cancer management. The TxGNN model predicts it may be effective for migraine disorder, but no clinical trials and no publications currently support this direction. The prediction is a computational output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the data compiled for this report (the product is known as a thyroid cancer diagnostic and adjunctive agent) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| US Market Status | Cancelled only (no currently valid license) |
| Number of NDAs | 1 (BLA020898, cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, thyrotropin alfa is recombinant human TSH. It binds the TSH receptor on thyroid cells and is used to stimulate thyroid tissue during thyroid cancer diagnosis and radioiodine ablation.
A plausible mechanism for migraine has not been established. The high score (99.98%) appears to reflect proximity in the knowledge graph rather than biological rationale. There is no known link between TSH receptor signaling and migraine pathophysiology, and no trials or literature were found to support one.
The other top predictions show the same pattern. Three more are migraine-related terms (migraine with brainstem aura, migraine susceptibility), which look like a redundant graph artifact. Others are Raynaud disease, pulmonary hypertension, rare skin disorders and hyperthyroidism, none with supporting evidence. Some are of concern:
- Hyperthyroidism: Biologically implausible and likely contraindicated, since TSH stimulates thyroid hormone production.
- Postural orthostatic tachycardia syndrome and pulmonary hypertension: Transient increases in thyroid hormone could worsen tachycardia or cardiovascular stress, so the direction of effect may be unfavorable.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA020898 (Cancelled) | Thyrogen (Genzyme Corporation) | Injection, powder, lyophilized, for solution | Not available in the compiled data |
Safety Considerations
Drug Interactions: The interaction screen identified 45 potential interactions, all of Moderate severity among those listed. They are concentrated in glucose-lowering agents, including:
- Metformin, acarbose, glimepiride, glipizide, glyburide, chlorpropamide, acetohexamide
- DPP-4 inhibitors and SGLT2 inhibitors (alogliptin, saxagliptin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin)
- GLP-1 receptor agonists (albiglutide, dulaglutide, exenatide, semaglutide)
- Insulins (human, aspart, aspart protamine)
Please refer to the package insert for other safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a graph-based model score alone, with no clinical trials, no literature and no plausible mechanistic link to migraine. The US license is also cancelled, and the package insert safety data has not yet been obtained.
To proceed, the following is needed:
- FDA package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data (for example, from DrugBank)
- A mechanistic hypothesis connecting TSH receptor signaling to migraine, followed by a literature and preclinical review
- Clarification of the current regulatory status of the cancelled BLA and its original approved indication
- Route compatibility assessment for any new indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.